Increased accumulation of magnetic nanoparticles by magnetizable implant materials for the treatment of implant-associated complications by Angrisani, Nina et al.
Angrisani et al. Journal of Nanobiotechnology 2013, 11:34
http://www.jnanobiotechnology.com/content/11/1/34RESEARCH Open AccessIncreased accumulation of magnetic nanoparticles
by magnetizable implant materials for the
treatment of implant-associated complications
Nina Angrisani1*, Franziska Foth1, Manfred Kietzmann2, Stephan Schumacher2, Gian Luigi Angrisani3,
Anne Christel4, Peter Behrens4 and Janin Reifenrath1Abstract
Background: In orthopaedic surgery, accumulation of agents such as anti-infectives in the bone as target tissue
is difficult. The use of magnetic nanoparticles (MNPs) as carriers principally enables their accumulation via an
externally applied magnetic field. Magnetizable implants are principally able to increase the strength of an
externally applied magnetic field to reach also deep-seated parts in the body. Therefore, the integration of
bone-addressed therapeutics in MNPs and their accumulation at a magnetic orthopaedic implant could improve
the treatment of implant related infections. In this study a martensitic steel platelet as implant placeholder was
used to examine its accumulation and retention capacity of MNPs in an in vitro experimental set up considering
different experimental frame conditions as magnet quantity and distance to each other, implant thickness and
flow velocity.
Results: The magnetic field strength increased to approximately 112% when a martensitic stainless steel platelet
was located between the magnet poles. Therewith a significantly higher amount of magnetic nanoparticles could
be accumulated in the area of the platelet compared to the sole magnetic field. During flushing of the tube system
mimicking the in vivo blood flow, the magnetized platelet was able to retain a higher amount of MNPs without an
external magnetic field compared to the set up with no mounted platelet during flushing of the system. Generally,
a higher flow velocity led to lower amounts of accumulated MNPs. A higher quantity of magnets and a lower
distance between magnets led to a higher magnetic field strength. Albeit not significantly the magnetic field
strength tended to increase with thicker platelets.
Conclusion: A martensitic steel platelet significantly improved the attachment of magnetic nanoparticles in an
in vitro flow system and therewith indicates the potential of magnetic implant materials in orthopaedic surgery. The
use of a remanent magnetic implant material could improve the efficiency of capturing MNPs especially when the
external magnetic field is turned off thus facilitating and prolonging the effect. In this way higher drug levels in the
target area might be attained resulting in lower inconveniences for the patient.
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Figure 1 Magnetic nanoparticles enclosed in a nanoporous
silica shell. The inner pore volume of such particles can be used for
the future incorporation of drugs; the outer surface can be employed
to bind fluorescent molecules for imaging and biomacromolecules for
improving biocompatibility.
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Implant related infections as well as non- or poorly-
healing fractures still issue a challenge to the physician
in charge. Between 2003 and 2009, about 1.38 million
hip prostheses and 1.01 million knee prostheses have
been implanted [1]. Depending on predisposing factors
1-7% develop implant-related infections [2,3]. This rate
even rises to 13.9% after surgically fixed open fractures
[4]. To avoid infections, systemically administered anti-
biotics [5] are most commonly used. Besides, antibiotic
chains [6] or antibiotic implant coatings [3] are applied
as an approach of a close-to-implant administration.
However, the general necessity and adequacy is ques-
tionable as a prophylactic perioperative antimicrobial
treatment cannot be a long-term solution in respect of
increasing antibiotic resistance.
Moreover, selective treatment of acute inflammatory
processes still remains difficult mainly due to insufficient
agent accumulation in the peri-implant area after sys-
temic administration. Thus, excessive drug levels may be
necessary to reach adequate concentrations within the
target tissue. Therewith the risk of undesirable side
effects increases markedly while, however, in many cases
success of the treatment is not achieved [7].
The use of magnetic nanoparticles (MNPs) as carriers
principally enables the accumulation of either pharma-
ceuticals (e.g. chemotherapeutics, antibodies, peptide
therapeutics) or oligonucleotides and growth factors via
external applied magnetic fields in selective areas of the
organism. For this purpose different types of MNPs have
been developed in recent years which have properties
like low toxicity, adequate circulation times or control-
lable magnetic responsiveness [8]. Most previous studies
focussed on their implementation in tumour treatment
[9] while another application under research is the
transport of genetic material or stem cells via MNP-
incorporation [10,11].
Although numerous animal studies were able to proof
the mechanism of action of magnetically driven drug
delivery during the last 25 years the transfer to clinical
use has failed as yet [12]. One of the main reasons for
this is the decrease of the magnetic field strength as a
function of distance from the generating magnet [12].
However, magnetizable implants are principally able to
increase the strength of an externally applied magnetic
field. Thus, adequately designed magnetic nanoparticles
could be satisfactorily accumulated in the target tissue.
Already in 1997, this concept has been reported for non-
porous superparamagnetic nanoparticles in the cardiovas-
cular system [13]. Recent studies consider wires, stents
and seeds [14]. So far, no work concentrated on magnetic
plates for orthopaedic applications. Unfortunately, the
accumulation of agents such as anti-resorptives, anti-
infectives or anabolics in the bone as target tissue isespecially difficult [15]. Therefore, the integration of bone-
addressed therapeutics in nanoporous shells around MNPs
and their accumulation at the orthopaedic implant would
enable the orthopaedist to considerably improve the treat-
ment of the complications described above. Austenitic
steel 316 L or titanium alloys are commonly used in
orthopaedic surgery. They provide only poor magnetic
properties. In contrast ferritic or martensitic stainless steel
holds properties like significantly higher permeability and
coercivity. While martensitic materials provide lower
maximum permeability than ferritic ones, their coercivity
excels.
The aim of the present study was to examine the
suitability of a martensitic steel platelet (Type 1.4122) on
the ability to accumulate magnetic nanoparticles in an
in vitro setup. These particles consist of a magnetic core
composed of magnetite (Fe3O4) enclosed by a nanopo-
rous silica layer [16] which serves for the future incor-
poration of drugs (Figure 1).Results
Basic experiments
Lower values of r basic indicate higher amounts of accu-
mulated MNPs. The standard setup parameters for the
basic experiments included a flow velocity of 1 mm/s, a
platelet thickness of 3 mm with 2×2 magnets mounted
at a distance of 1.5 cm. If parameters differed or were
added for specific setups values are given at the respect-
ive paragraph.Influence of tube
At flow velocities of 1 mm/s and 8 mm/s, sedimented
MNPs within the tube were visible to the naked eye.
Generally, the concentration of MNPs in the collected
sample was lower than in the tube sample. A significant
lower concentration of MNPs sedimented in the tube at
8 mm/s (r basic = 0.798 ± 0.072) than with the lower rate
of 1 mm/s (r basic = 0.64 ± 0.122).
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Compared to the influence of the tube alone the non-
magnetic 2 mm platelet could not increase the MNP
accumulation (r basic = 0.736 ± 0.049). The platelet mag-
netized to saturation generated a low magnetic field
(0.0012 T) and accumulated a significantly higher
amount of MNPs (r basic = 0.551 ± 0.074) than the non-
magnetic platelet.
Regarding platelet thicknesses of 1 mm, 2 mm and
3 mm in combination with mounted magnets, it seems
that the quotient decreases slightly for thicker platelets
(r basic 1 mm = 0.12 ± 0.03; r basic 2 mm = 0.11 ± 0.05; r basic
3 mm = 0.11 ± 0.05). However, these differences were not
statistically significant.Figure 3 Influence of tube, magnets and platelet on the
accumulation of MNPs. r basic values (light grey) and magnetic flux
density (dark grey) for different experimental setups. The
accumulation of MNPs increases with increasing magnetic field
strength. Asterisks (*) mark significant results (p < 0.05).Influence of magnet quantities and magnet distances
As expected, the magnetic flux density generally increa-
sed with increasing number of magnets and decreasing
distance between the magnets. Therefore the highest
magnetic flux density (0.55 T) could be generated by
2×2 magnets at a distance of 15 mm (Figure 2) which
resulted in a r basic of 0.134 ± 0.027.
A further increase in magnetic flux density (0.62 T)
could be obtained when the 3 mm platelet was additionally
mounted. Accordingly, a slightly lower ratio was reached
(r basic 15 mm = 0.11 ± 0.05). The r basic values with platelet
for 55 mm/0.55 T and 35 mm/0.51 T were 0.25 ± 0.06 and
0.13 ± 0.04, respectively.
Figure 3 summarizes and compares the results of the
predominant experimental setups.Influence of flow velocity
Additionally to the standard flow velocity of 1 mm/s,
2 mm/s, 8 mm/s and 0.5 mm/s were examined.
In comparison to the influence of the tube alone
significantly higher amounts of MNPs accumulated in
the tube sample with platelet and 2×2 magnets mounted
at a flow velocity of 1 mm/s. Generally, the faster the MNP
solution passed through the system, the less MNPsFigure 2 Magnetic flux density in dependence of the number
of magnets and the distance between magnets.accumulated within the tube (Figure 4, rbasic 8mm/s = 0.43 ±
0.06; rbasic2mm/s = 0.14 ± 0.02; rbasic0.5mm/s = 0.08 ± 0.01).
Compartment trial
To determinate the quantity of nanoparticles inside the
different compartments of the tube system, the volume
of three different compartments (I-III, Figure 5) was iso-
lated and examined instead of investigating the content
of the complete tube in one.
All compartments showed different quotients. Com-
partment I (beginning of flow chamber to beginning
of magnets) accumulated a lower amount of MNPs
(r basic = 0.23 ± 0.09) than compartment II (tube in the
region of the magnets; r basic = 0.10 ± 0.04). The lowest
amount of MNP accumulation was found for compartmentFigure 4 MNP accumulation at different flow velocities. The
capture capacity is represented by the ratio of the concentrations
measured in the collected sample and the tube sample. r basic: ratio
of basic experiments; ccs: concentration of collected sample; cts:
concentration of tube sample. All differences except for 1 mm/s vs.
2 mm/s are highly significant (p ≤ 0.01).
Figure 5 Compartment trial. Compartments I-III for determination
of the nanoparticle concentration inside the different parts of the
tube (a-e, *: see Figure 7).
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than in compartment I and II.
Transfer experiments
Lower values of r transfer indicate higher amounts of kept
MNPs.
r basic and r transfer cannot be compared to each other.
Retention capacity of tube after MNP accumulation with
2×2 magnets
After the MNP fluid had passed the system and the
magnets had been removed the tube was able to retain a
low amount of MNPs during the flushing of the system
with deionised water (r transfer = 0.17 ± 0.03) (Figure 6).Figure 6 Flushing experiments simulating the in vivo situation. Retent
flushing of the system with non-MNP-containing deionized water. The low
found when the platelet remains in place after removal of the magnets (r tRetention capacity of tube after MNP accumulation with
2×2 magnets/3 mm platelet
A higher amount of MNPs remained within the tube
when the magnets and the platelet were mounted in the
first run before flushing. Compared to the setup with
magnets only, (r transfer = 0.15 ± 0.05) was not significantly
different (Figure 6).Retention capacity of platelet after MNP accumulation with
2×2 magnets/3 mm platelet
A significant increase in retention capacity was observed
during the flushing cycle when solely the magnets were
removed from the flow chamber and the magnetized
platelet was left in place (r transfer = 0.13 ± 0.03; p ≤ 0.01)
(Figure 6).Discussion
While the main focus in implant related magnetic drug
targeting is laid on stents [17,18] the benefit of mag-
netizable orthopaedic implant materials would be remar-
kable. As described above implant related infections in
arthroplasty or poorly healing fractures play an important
role in orthopaedic surgery due to insufficient agent accu-
mulation at inserted implants. E.g. adequately designed
osteosynthesis plates, medullary nails or endoprostheses
with magnetic properties would enable a time-inde-
pendent administration of antibiotics at the moment when
an infections occurs therewith minimizing resistance-
supporting prophylactic antibiosis or undesirable side-
effects due to high-dose antibiosis.
The present study aimed to examine the capacity of a
martensitic steel platelet as implant placeholder to improveion capacity of the tube or platelet and tube, respectively, during
est r transfer and therefore the highest accumulation of MNPs could be
ransfer = 0.13 ± 0.03).
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based in vitro experimental setup.
The influence of the setup components like tube,
number of magnets used, distance between magnets,
flow rate or platelet thickness were systematically varied
in a set of experiments which aimed to mimic the
in vivo situation.
One of the major problems in targeting magnetic
nanoparticles in vivo is to induce magnetic fields of
sufficient strength in deeper parts of the body [12,19].
On the other hand the magnetic field gradient which is
established by the magnetic field decreasing as a func-
tion of distance is essential to be able to target magnetic
nanoparticles site-specifically at all [12]. The key param-
eters influencing the capture of magnetic nanoparticles
(MNPs) are the magnetic field and the flow velocity
[17,19-21].
In the present experimental setup, permanent neody-
mium-based magnets were able to create a magnetic
field of 0.55 T when arranged two by two with a distance
of 15 mm. Räthel et al. reported on a magnetic field of
up to 0.4 T generated by neodymium magnets in com-
bination with a magnetizable stent in an in vitro experi-
mental setup relatively similar to the presented study
[17]. However, no data are given about the magnetic
field strength without magnetizable implant so no evalu-
ation on the field enhancing properties of the Nickel
plated stent used could be done. Nobuto et al. reported
an increased accumulation of MNPs in vivo after the
application of a magnetic field of 0.4 T [22]. However,
they did not use any implant material to further increase
the magnetic flux density, so that the distance between
the poles was 10 mm. Without field enhancing internal
magnetizable material the magnetic field strength has to
exceed 1 T to target areas which are deeper than 5 cm
within the body [23]. Therefore, the successful expe-
rimental setup of Nobuto et al [22] would be difficult to
apply to larger species.
As mentioned above the fluid flow velocity is one of
the two key parameters, so the influence of different
flow velocities was examined. As expected, higher flow
velocities led to lower amounts of captured MNPs which
corresponds to results on the capture efficiency of
MNP-loaded cells [21]. Similar results were reported by
Räthel et al. for the retention of magnetic microbubbles
at different flow velocities [17]. Therefore, the site-
specific flow velocity has to be considered when mag-
netic drug targeting strategies are developed. While
different groups are working on cardiovascular implants
which are faced with higher flow velocities [13,24] the
treatment of any disease outside the cardiovascular
system would have to regard lower hydrodynamic forces.
Since for the intended orthopaedic application small
arteries and capillaries with a blood flow velocity of 1 mm/s[25] as well as neovascularization are the main issues of
interest, the standard flow velocity of the current in vitro
experimental setup was chosen to be 1 mm/s. Principally,
the blood flow velocity within the bone is markedly slower
than in the adjacent tissue [26,27]. Furthermore, enhanced
blood supply in the injured area via e.g. neovascularization
probably would increase the local amount of MNPs. Thus,
higher capture efficiency could be reached during in vivo
experimental setups. As different other studies show there
are certainly further parameters closely linked to the blood
system like vessel diameter, flow behaviour or fluid vis-
cosity which would influence the capture efficiency of
magnetic nanoparticles [20,28]. For example the blood as
Non-Newtonian fluid with its velocity-dependant viscosity
would impact the MNP movement inside the vessel. Lar-
ger vessel diameters would mean farther distances which
have to be overcome by the MNPs. Considering all this,
an in vitro experimental setup usually would not succeed
in exactly mimicking the in vivo situation. Nevertheless,
principle conclusions could be drawn by changing particu-
lar parameters. The intended application for the present
study would involve mainly capillaries with a diameter
smaller than the chosen 3 mm plastic tube. Therefore the
accumulation of MNPs in vivo is not expected to be worse
due to diameter reasons. Further in vitro studies consi-
dering MNP carrier fluids of different viscosities would
complement the presented results.
To diminish the influence of blood flow velocity,
strong ferromagnetic implants or MNPs of larger core
diameter would be reasonable [19].
While martensitic steels provide smaller maximum
permeability than ferritic ones, their coercivity excels.
Applied to orthopaedic implant properties, they would
be less susceptible to demagnetization and thus offer
good magnetic remanence while the intensification of
the magnetic field is inferior. In contrast, austenitic
stainless steel is generally regarded to be non-magnetic
if not special processing such as cold-working induces
martensitic phases. The current setup proved a sig-
nificant increase in capture capacity of MNPs due to an
elevation of the magnetic field strength to approx. 112%
when the martensitic steel platelet was applied. Due to
its magnetic field, albeit low, even the saturated mag-
netized platelet was able to significantly increase the
amount of captured nanoparticles without any further
external magnetic field. Other studies also showed a
positive effect on the magnetic field strength by applying
stainless steel implants [18,24,29]. Polyak et al demon-
strated an increase in cell capture capacity of MNP-loaded
bovine aortic endothelial cells in vitro as well as in vivo
when the magnetic field was combined with a 304-grade
stainless steel stent [18]. Depending on its production
process, 304-grade stainless steel could offer magnetic
responsiveness in contrast to most other members of this
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316 L. The stents used by Polyak et al were able to capture
20% of targeted cells within 50 minutes [18]. Forbes et al
also used 304-grade stainless steel stents to examine their
capture capacity in comparison to 302-grade stainless steel
springs [24]. Additionally they applied a soft magnetic
coating of different thickness by electroplating. Both
groups could show the enhanced performance of mag-
netic drug targeting by combining the external magnetic
field with an austenitic stainless steel implant. However,
they only examined the capture capacity during the direct
influence of the magnetic field. Since the coercivity of
austenitic steels is markedly inferior to that of martensitic
steels, the effect described will most probably be removed
after leaving the magnetic field.
Although a higher permeability than that of the mar-
tensitic steel platelet used in the present study would be
preferable, the results proved that the choice of reman-
ent magnetic material with a higher coercivity could lead
to an extended duration of MNP capture effect. MNPs
which were not captured during the external magnetic
field application could still be captured afterwards due
to the remanent implant material. Malheiro et al charac-
terized 444 ferritic stainless steel as non-cytotoxic and
non-inflammatory with a good corrosion resistance [29].
Its property to support osteoblast attachment, prolifera-
tion and differentiation during in vitro cell culture tests
makes it attractive for all orthopaedic applications. As a
ferromagnetic material its ability to intensify the mag-
netic field excels both austenitic and martensitic steels.
However, its coercivity is equally inferior to martensitic
materials as austenitic steels.
It has to be kept in mind that the implantation of
magnetizable implant materials with high permeability
could also bear some disadvantages as, for example, MRI
examinations would not be feasible as already mentioned
by Forbes et al [24]. Fracture fixation with such mate-
rials for a definite time period with subsequent removing
of the implant is not viewed critically but long term
applications as for hip and knee prostheses have to con-
sider this possible later limitation of diagnosis.
Considering all presented deliberations, the material
for an implant directed magnetic drug targeting for
orthopaedic applications has to be chosen carefully, par-
ticularly concerning the main issues biocompatibility,
magnetic permeability and coercivity and a broad area of
research exists.
In the field of magnetic drug targeting MNPs of different
designs are used. The most commonly used MNPs are iron
oxides, namely maghemite and magnetite, which appear to
have the most potential [30] and are usually applied core-
shell particles [31]. Nieciecka et al specified the optimal
size of iron oxide nanoparticle to be 10-100 nm [32] which
corresponded to the declarations of Chomoucka et al andXie et al [31,33]. They stated that the optimal size of mag-
netic nanoparticle has to be less than 100 nm and 50 nm
respectively to avoid a rapid clearance of MNPs through
the reticulo endothelial system (RES) and to enhance their
extravasation ability [33]. On the other hand larger MNPs
could probably decrease undesired side effects. Studies
using gold nanoparticles and polystyrene beads have
reported for particles >80 nm to be partially or totally
excluded of placental uptake [34,35]. Besides the core
material, the core diameter determines the magnetic mo-
ment of MNPs [20]. However, the core diameter cannot
be unlimitedly enlarged due to danger of thrombosis [20].
Modification of MNPs with e.g. silica or polymers aim to
achieve enhanced physical and/or chemical properties
[31]. Chomoucka et al described differently applied modi-
fications in their review in 2010. They concluded that
surface adaption via e.g. different coatings allows the
attachment of drugs and the adjustment of biochemical
properties [31]. Also, Nieciecka et al stated that cationic
coatings on MNPs promote cell uptake [32]. The MNPs
used in the present study represent rather large nano-
particles but their structure combining a solid magnetic
core with a nanoporous silica layer offers numerous possi-
bilities of functionalization. Drugs can be internalized into
the internal pore volume of the silica layer while (bio-)
polymers attached to the outer surface could increase
biocompatibility, influence clearance properties and pro-
mote affinity to the target tissue. Due to the rich chemistry
of silica surface modification, the most appropriate che-
mical modification strategy can be chosen. Transferred to
orthopaedic applications the most qualified drug for the
respective clinical situation can be used. Also Gupta et al
coupled MNPs to various proteins and showed that
underivatized MNPs were internalized by fibroblasts
whereas coated MNPs attached to cell membranes [36].
Gentamicin coated nanoparticles could be successfully
used in vitro to treat implant related infections [37].
Although numerous studies have been performed to
examine differently designed MNPs countless further
possibilities remain to discover and examine. Nanoporous
silica nanoparticles with internalized magnetic nanopar-
ticles appear to be especially promising due to the gener-
ally favourable biocompatibility of nanoporous silica and
the possibility to selectively address the inner pore volume
(for uptake and release of a drug) as well as the outer
surface (for attachment of functional molecules, e.g. fluo-
rophores for imaging, antibodies for targeting, polymers
for biological properties) of these particles [38].
Conclusion
The current in vitro study proved an increased attach-
ment of magnetic nanoporous silica nanoparticles at a
martensitic steel platelet (Mat.No. 1.4211) and therewith
introduces the idea of implant-directed magnetic drug
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remanent magnetic implant material could improve the
efficiency of capturing MNPs especially when the exter-
nal magnetic field is turned off. In this way higher drug
levels in the target area might be attained resulting in
lower inconveniences for the patient.
Materials and methods
Magnetic particles, implant-like platelets, magnets
The magnetic core-shell nanoparticles were produced at
the Institute of Inorganic Chemistry, Leibniz University
of Hannover. All chemicals for the synthesis, except
ethanol, were purchased from Sigma Aldrich Chemie
GmbH (Munich, Germany) and used without further
purification. Ethanol (free from denaturing agents) was
purchased from Merck (Darmstadt, Germany).
The magnetic nanoparticles for the core were synthe-
sized according to Hegmann et al [39] 1.41 g (4 mmol)
iron(III)acetylacetonate (Fe(acac)3) were added to a solu-
tion of 100 ml ethanol and 100 ml pure water. After-
wards, this solution was purged with nitrogen for 1 h.
1.51 g (40 mmol) sodium borohydride (NaBH4) were
added under vigorous stirring and a nitrogen atmosphere.
The colour of the solution changed from red to orange
and then to black. After 1 h the formed nanoparticles were
magnetically separated and washed with water and etha-
nol three times before being dried at 60°C.
To stabilize the nanoparticle suspension 60 mg of the
Fe3O4 nanoparticles were suspended in 5 ml trisodium
citrate solution (0.5 M) by ultrasonification (USC200TH,
60 watt, VWR International GmbH, Darmstadt, Germany)
and stirred at 60°C overnight. The nanoparticles were
magnetically separated (DynaMag 15 system, Life Tech-
nologies, Carlsbad, California, USA) and washed with
water and ethanol. Finally, a magnetic fluid with a nano-
particle concentration of 30 mg · ml-1 was produced by
suspending the product in 2 ml pure water.
The synthesis of the magnetic core-shell nanoparticles
was adapted from Zhang et al [40]. The prepared mag-
netic fluid was suspended in a mixture of 40 ml pure
water and 160 ml ethanol. Subsequently, 2 ml ammonia
(NH3 · H2O, 25%) and 0.75 ml (3.4 mmol) tetraethyl
orthosilicate (TEOS) were added and the reaction mix-
ture was stirred at room temperature overnight (12 h).
After magnetic separation the particles were washed
with water and ethanol four times. The whole product
was then suspended in 10 ml pure water. 3 ml of this
suspension were added to 120 ml pure water and 60 ml
ethanol. Afterwards, 0.25 g (0.7 mmol) hexadecyltrime-
thylammonium bromide (CTAB) were added followed
by the dropwise addition of 0.15 ml (0.7 mmol) TEOS.
The mixture was stirred at room temperature overnight.
The fabricated core-shell nanoparticles were then mag-
netically separated and washed with water and ethanolup to four times. After drying the nanoparticles at 60°C
they were calcined at 550°C for 5 h with a heating rate
of 1 K · min-1 to remove the CTAB.
Two different types of core-shell nanoparticles were
obtained as identified by TEM (JEM-2100 F, JEOL ltd.,
Tokyo, Japan) analysis: Larger particles (500 nm) which
consist of a dense silica core and a nanoporous silica shell
(but contain no magnetic naoparticles) and smaller parti-
cles (150 – 250 nm) which consist of magnetic nanopar-
ticles embedded within a nanoporous silica shell. The
smaller magnetic core-shell nanoparticles were magnetic-
ally separated from the larger non-magnetic particles.
For the present study, these particles were dispersed in
distilled water to a final concentration of 500 μg/ml. To
ensure a good dispersion an ultrasonification treatment
was applied four times for 10 minutes before each experi-
ment, alternating with agitation to avoid sedimentation.
Platelets (1.7 mm × 3.7 mm) of martensitic steel 1.4122
(Sürth Stahl- und Metallhandel Laatzen, Germany, relative
magnetic permeability μr = 3.61) were chosen as implant
simulator. They were produced at the Institute of Mate-
rials Science, Leibniz University of Hannover. Three
different types were cut from 200 mm as cast round stock:
one platelet each with a thickness of 3 mm, 2 mm and
1 mm.
To establish the magnetic field four Neodym Power
Magnets (N45, 40 mm × 40 mm × 10 mm, axially mag-
netized) were obtained from ricoo, E.N.Z. Engineering
OHG, Emmendingen.
Experimental setup
A custom designed poly-methyl-methacrylate (PMMA)
flow chamber (Institute of Materials Science, LUH,
Figure 7a) provides a mounting system to position the
neodymium magnets (Figure 7b, attracting each other)
and the implant-like platelet (Figure 7c). The flow exper-
iments were set up using an infusion pump (B.Braun
Perfusor Space, Figure 7f) passing the MNP-containing
solution via a 50 ml syringe and two PVC-tubes (150 mm
and 100 mm in length, both 3 mm in diameter, connected
via a three-way stopcock) through the flow chamber. The
second tube (Figure 7e) ends in a small collecting con-
tainer (Figure 7d). Magnetic flux density was measured
constantly by a teslameter (FH 54 Gaussmeter, Magnet-
Physik Dr. Steingroever GmbH, Figure 2, *) where the
platelet was positioned between the magnets and directly
next to the tube.
Corresponding to the natural blood flow velocity in
capillaries [26]. 2 ml of the NP-solution were passed
through the system with a flow velocity of 1 mm/s in all
experiments, unless stated otherwise. To reach this flow
velocity, the infusion pump was set to a flow rate of
25.44 ml/h. At the end of the system 1.2 ml of the NP-
solution dripped into the collecting container. This sample
Figure 7 Experimental set up. a) custom designed flow chamber, b)
neodymium power magnets, c) martensitic steel platelet, d) collecting
container, e) PVC tube 100 mm, f) infusion pump, *) teslameter.
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Eppendorf tube. After removing the magnets the tube was
carefully pulled out of the chamber. An air filled syringe
was set on the three-way stopcock and deflated into the
tube. Therewith the content of the tube (0.8 ml) which
was located in the magnetic field was emptied into a sec-
ond collecting container (“tube sample, ts”) and afterwards
transferred into an Eppendorf tube as well.
Each setting was identically performed eight times. For
a higher statistical validation the experiments “tube, 2×2
magnets, 15 mm distance, and 1 mm/s, without and
with 3 mm platelet” (standard experiment) as well as
“the influence of the tube at a velocity of 1 mm/s” were
additionally repeated on three separate days each.
Analysis of capture efficiency
The samples were analysed colorimetrically at the Institute
of Pharmacology, Toxicology and Pharmacy using a MRX
microplate reader at a wavelength of 405 nm (Dynatech,
Denkendorf). The detection limit was 35 μg/ml (intraday/
interday precision for 2000 μg/ml: 0.7%/0.3%; intraday/
interday precision for 31.25 μg/ml: 4.7%/15.6%).
For calibration purposes, an MNP solution with a con-
centration of 2000 μg/ml was used for a serial dilution
at a ratio of 1:2. 100 μl of each concentration were trans-
ferred into a 96 well plate. Additionally, two samples of
100 μl distilled water were measured as blank and the
collected sample and the tube sample were measured in
triplicate of 100 μl each.
The resulting optical density was converted into the
MNP concentration in μg/ml using the calibration curve.For an easier comparison, a ratio of the concentrations
of the collected sample (ccs) and of the tube sample (cts)
was computed according to Equation 1:
rbasic ¼ CcsCts ð1Þ
with r basic: quotient for the basic experiments (see
Figure 4)
ccs: concentration of collected sample.
cts: concentration of tube sample.
Lower values of r basic indicate higher amounts of
accumulated MNPs.
Results are given as means ± standard deviation. Statis-
tical analysis was performed with IBM SPSS Statistics
20.0.0. All quotients were tested for normal distribution.
Either student’s t-tests or univariate ANOVA (signifi-
cance level p = 0.05) were performed including analysis
of variance homogeneities. In case of significant ANOVA
results, multiple comparisons were made via post-hoc
tests (tukey and games-howell, respectively).
Basic experiments
Influence of tube
To determine the influence of tube – MNP interaction
and sedimentation the MNP solution was passed through
the chamber without mounted magnets or platelet. Besi-
des the standard flow velocity of 1 mm/s, 8 mm/s was
examined as maximum flow velocity.
Influence of platelet and platelet thickness
The capacity of the martensitic steel platelet itself with-
out mounted magnets to accumulate MNPs was tested.
The experiment was performed in two variations: first
with the non-magnetic 2 mm platelet and second with
the same platelet after having been exposed to a mag-
netic field (saturated magnetized platelet).
Furthermore the influence of different platelet thick-
nesses was studied by performing the experiment with
2×2 magnets (distance between the magnets 15 mm)
and one mounted platelet of 3 mm, 2 mm and 1 mm
thickness each.
Influence of magnet quantities and magnet distances
The magnetic flux density was determined for 2×1 and
2×2 magnets, each with a distance between the magnets
of 15 mm, 35 mm and 55 mm, respectively. To achieve
the different distances PMMA bar spacers (10 mm ×
15 mm × 60 mm) were placed between the magnets
inside the flow chamber. For the combination with the
highest flux density the MNP accumulation capacity has
been investigated.
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and distances of 15 mm, 35 mm and 55 mm.
Influence of flow velocity
According to the different vessel sizes in the human
body different flow velocities were studied. The MNP so-
lution passed the system with 2×2 magnets and mounted
3 mm platelet. Besides 1 mm/s which corresponds to the
flow velocity in capillaries (see above), the infusion
pump was set to 0.5 mm/s (0.5× capillary flow), 2 mm/s
(2× capillary flow) and 8 mm/s as the maximum flow
velocity possible.
Compartment trial
To determine the different quantities of nanoparticles
inside the different compartments of the tube system the
experiment was performed as before (2×2 magnets,
15 mm distance) but instead of emptying the complete
tube after removing it from the flow chamber, three dif-
ferent compartments (I-III, Figure 5) were marked and
isolated via clamps. Subsequently, the sample of each
section was withdrawn individually: the tube part from
the beginning of the flow chamber to the beginning of
the magnets (I), the tube part in the region of the mag-
nets (II), the part from the end of the magnets to the
end of the tube (III).
Transfer experiments
To simulate the in situ situation within an organism a
series of experiments was performed regarding the flush-
ing effect of blood flow. Three different experimental
setups were used:
Retention capacity of tube after MNP accumulation with
2×2 magnets
The experiment was performed with mounted magnets
(distance 15 mm) but without platelet. After passing the
flow chamber the first collected sample (cs1) was retrieved
and the magnets were removed from the flow chamber.
Next, 2 ml of none-MNP-containing deionised water was
passed through the tube system simulating the flushing
through the constant blood flow in the vessels. The sec-
ond collected sample (cs2) as well as the tube sample (ts)
were taken.
Retention capacity of tube after MNP accumulation with
2×2 magnets/3 mm platelet
The standard experimental setup was performed (2×2
magnets, 15 mm distance, 3 mm platelet, 1 mm/s) and cs1
was retrieved. Both platelet and magnets were removed
from the flow chamber and flushing was performed
according to 5.1.Retention capacity of platelet after MNP accumulation with
2×2 magnets/3 mm platelet
The experimental setup corresponded to 5.2 but after
the first passage and collection of cs1 only the magnets
were removed from the flow chamber. During the flush-
ing with 2 ml non-MNP-containing deionised water the
platelet stayed in the flow chamber to determine its
capacity to retain MNPs in its vicinity in the absence of
a magnetic field. Cs2 and ts were taken as above.
Analysis of samples
After colorimetric measurement and computation of
MNP concentration as described the ratio was calculated
following Equation 2:
rtransfer ¼ CCS1 þ CCS2ð Þ=2Cts ð2Þ
with r transfer: quotient for the transfer experiments
ccs1: concentration of collected sample 1.
ccs2: concentration of collected sample 2.
cts: concentration of tube sample.
Lower values of r transfer indicate higher amounts of kept
MNPs. Due to the fact that the solution which was used
to flush the system did not contain magnetic nanoparti-
cles, we emphasize that r basic and r transfer cannot be com-
pared to each other.
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